The Impact of Postoperative Tumor Burden on Patients With Brain Metastases

Amir Kaywan Aftahy, Melanie Barz, Nicole Lange, Lea Baumgart, Cem Thunstedt, Mario Antonio Eller, Benedikt Wiestler, Denise Bernhardt, Stephanie E. Combs, Philipp J. Jost, Claire Delbridge, Friederike Liesche‐Starnecker, Bernhard Meyer, Jens GemptFrontiers in Oncology 2022 · DOI

This study, published in Frontiers in Oncology, provides a quantitative look at how much "leftover" tumor matters after brain metastasis surgery. By analyzing over 700 patients, the researchers established that postoperative residual tumor burden (RTB) is a primary predictor of survival, identifying specific volumetric cutoffs that significantly impact patient outcomes regardless of subsequent radiation therapy.

TL;DR

Residual tumor volume after surgery is a critical, independent predictor of survival for patients with brain metastases. Achieving a residual tumor burden (RTB) of less than 1.78 cm³—and ideally complete cytoreduction—significantly extends life expectancy, even when postoperative radiotherapy is administered.

What Problem Does This Paper Address?

Brain metastases (BMs) were historically viewed as well-circumscribed "balls" that could be easily separated from healthy brain tissue. However, recent pathological evidence suggests they can be more infiltrative than previously thought.

While "Gross Total Resection" (GTR) is a gold-standard goal in many neurosurgical procedures, its specific impact on survival in the context of BMs has been debated and under-quantified. Surgeons often rely on their own intraoperative estimates of how much tumor they removed, which are notoriously inaccurate. This paper seeks to replace those "gut feelings" with hard data by using early postoperative MRI to measure exactly how much tumor remains and how that volume correlates with survival.

Methods

The researchers conducted a retrospective analysis of 704 adult patients who underwent surgery for brain metastases at the Technical University Munich between 2007 and 2020.

  • Imaging: The study utilized early postoperative MRI (performed within 72 hours of surgery). This timing is critical to distinguish actual residual tumor from postoperative changes like inflammation or scarring.
  • Volumetric Analysis: Instead of just saying "some tumor is left," they used manual segmentation software (Origin®) to calculate the exact volume of contrast-enhancing residual tumor in cubic centimeters (cm³).
  • Statistical Modeling: They employed multivariate Cox regression to ensure that RTB was an independent factor, controlling for variables like age and functional status (KPSS). They used "maximally selected log-rank statistics" to find the specific "tipping point" volumes where survival rates significantly diverged.

Datasets

The study used a large, single-center clinical dataset:

  • Cohort: 704 patients (selected from an initial 761).
  • Scope: 13 years of clinical data, including preoperative tumor burden, postoperative RTB, age, histopathological entity (cancer type), and type of radiotherapy (Whole Brain vs. Stereotactic).

Key Insights and Ideas

  • The "Myth" of the Well-Defined Lesion: The study reinforces the idea that BMs are infiltrative. Because they aren't always perfectly self-contained, surgical "completeness" is harder to achieve than intraoperative visual inspection might suggest.
  • The 1.78 cm³ Threshold: The most striking insight is the identification of a clear cutoff. Patients with a total RTB of less than 1.78 cm³ had significantly better survival than those above it.
  • Targeted vs. Total Burden: For patients with multiple metastases, the researchers found that reducing the "targeted" lesion (the one operated on) to less than 0.28 cm³ was a key threshold for improved outcomes.
  • Surgery vs. Radiation: While radiotherapy is essential, the study found that the quality of the surgery (the RTB) remains a dominant predictor of survival. Radiation cannot entirely "make up" for a high residual tumor volume.

Key Results

  • Complete Cytoreduction: Achieved in 69.2% of patients.
  • Median Survival: 6 months across the entire cohort.
  • RTB as a Predictor: In multivariate analysis, postoperative tumor burden was a highly significant predictor of survival (p = 0.0036).
  • Specific Cutoffs:
    • RTB < 1.78 cm³ for all patients (p = 0.0022).
  • RTB < 0.28 cm³ for the specific targeted metastasis (p = 0.0047).
  • Age < 67 years was also identified as a significant survival cutoff (p < 0.001).
  • Radiotherapy Impact: Stereotactic radiotherapy (SRS/HSRS) showed a significant positive impact on survival (p < 0.001), particularly in patients with single metastases.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: The study looks backward at existing data, which can introduce selection bias (e.g., only "healthier" patients might have been selected for surgery and follow-up MRI).
  • Systemic Therapy Evolution: Over the 13-year study period, systemic treatments (chemotherapy, immunotherapy) for primary cancers like lung and breast cancer improved significantly. This study could not fully account for the impact of these evolving drug regimens on overall survival.
  • Single-Center Data: While the sample size is large, the data comes from one institution.

Future Work: The authors suggest that these volumetric cutoffs should be validated in prospective, multi-center trials to establish standardized "surgical success" metrics in neuro-oncology.

Summary updated

Abstract

RTB is a strong predictor for survival. Maximal cytoreduction, as confirmed by postoperative MRI, should be achieved whenever possible, regardless of type of postoperative radiotherapy.
BibTeX
@inproceedings{aftahy2022impact,
  author = {Amir Kaywan Aftahy and Melanie Barz and Nicole Lange and Lea Baumgart and Cem Thunstedt and Mario Antonio Eller and Benedikt Wiestler and Denise Bernhardt and Stephanie E. Combs and Philipp J. Jost and Claire Delbridge and Friederike Liesche‐Starnecker and Bernhard Meyer and Jens Gempt},
  title = {{The Impact of Postoperative Tumor Burden on Patients With Brain Metastases}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.869764},
}
Figure